LAMTOR2

Across TCGA pan-cancer cohorts, LAMTOR2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LAMTOR2 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LAMTOR2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LAMTOR2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where LAMTOR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.927	0.658	.005	20	view →
LUAD	DFS	Median	II,III,IV	0.741	1.000	.001	9	view →
LSCC	OS	Median	II,III,IV	1.000	0.879	.015	3	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
GBM	DFS	Quartile	All	0.618	0.789	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LAMTOR2–HNSC (DFS)

Open the HNSC breakdown →